We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TDOC Partners With TytoCare to Expand At-Home Exam Capabilities
Read MoreHide Full Article
Key Takeaways
TDOC will integrate TytoCare's Home Smart Clinic to offer clinical-grade remote exams for members in 2026.
TytoCare's device delivers lung, heart, throat, ear, skin and temperature checks with AI Lung Sounds Suite.
TDOC's plan reflects rising demand for bringing advanced diagnostic tools directly into patient homes.
Teladoc Health, Inc. (TDOC - Free Report) is taking a significant step forward in virtual care by integrating TytoCare’s FDA-approved Home Smart Clinic into its popular Primary360 and 24/7 Care programs. Starting in 2026, some members will be able to access clinical-grade remote exams using TytoCare’s handy diagnostic device. This move represents one of the most comprehensive enhancements to in-home care options within the telehealth landscape.
TytoCare’s innovative technology enables remote assessment of lungs, heart, throat, ear, skin and temperature, closing like an in-person examination. The standout feature is its recently FDA-cleared AI-powered Lung Sounds Suite, which was recently honored as a TIME 2025 Best Invention. This tool can distinguish between the three most common abnormal lung sounds, marking a significant advancement, especially since respiratory issues account for over 40% of diagnoses on the TytoCare platform.
For TDOC, this integration strengthens its competitive edge at a time when virtual care providers are under pressure to demonstrate their long-term value and sustainability. For employers and health plans, this change could mean quicker interventions, a reduction in unnecessary ER visits and better ongoing care for chronic issues like asthma or hypertension. TytoCare’s extensive health dataset of over 7 million recorded exams boosts both diagnostic confidence and the accuracy of models.
This move also aligns with a broader trend in healthcare — bringing diagnostics closer to the patient. With more people wanting care at home, integrated AI diagnostics might soon be the norm instead of just a unique feature.
However, the execution of this plan will be key. The rollout is set to begin with a select group of customers, which indicates TDOC is cautiously testing adoption, utilization rates and reimbursement alignment. If executed well and reflects TytoCare’s historical performance, then this integration could become a scalable advantage.
TDOC’s Price Performance
Year to date, TDOC shares have declined 23% against the industry’s growth of 4.9%.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.12 per share has witnessed three upward revisions in the past 30 days against no movement in the opposite direction. BrightSpring Health Services beat earnings estimates in each of the trailing four quarters, with the average surprise being 45.1%. The consensus estimate for current-year revenues is pegged at $12.7 billion, suggesting 12.8% year-over-year growth.
The Zacks Consensus Estimate for Universal Health’s current-year earnings of $21.67 per share has witnessed six upward revisions in the past 30 days against no movement in the opposite direction. Universal Health beat earnings estimates in each of the trailing four quarters, with the average surprise being 15.2%. The consensus estimate for current-year revenues is pegged at $17.4 billion, suggesting 9.7% year-over-year growth.
The Zacks Consensus Estimate for Veracyte’s current-year earnings of $1.42 per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction. Veracyte beat earnings estimates in each of the trailing four quarters, with an average surprise being 45.1%. The consensus estimate for current-year revenues is pegged at $508.6 million, suggesting 14.1% year-over-year growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
TDOC Partners With TytoCare to Expand At-Home Exam Capabilities
Key Takeaways
Teladoc Health, Inc. (TDOC - Free Report) is taking a significant step forward in virtual care by integrating TytoCare’s FDA-approved Home Smart Clinic into its popular Primary360 and 24/7 Care programs. Starting in 2026, some members will be able to access clinical-grade remote exams using TytoCare’s handy diagnostic device. This move represents one of the most comprehensive enhancements to in-home care options within the telehealth landscape.
TytoCare’s innovative technology enables remote assessment of lungs, heart, throat, ear, skin and temperature, closing like an in-person examination. The standout feature is its recently FDA-cleared AI-powered Lung Sounds Suite, which was recently honored as a TIME 2025 Best Invention. This tool can distinguish between the three most common abnormal lung sounds, marking a significant advancement, especially since respiratory issues account for over 40% of diagnoses on the TytoCare platform.
For TDOC, this integration strengthens its competitive edge at a time when virtual care providers are under pressure to demonstrate their long-term value and sustainability. For employers and health plans, this change could mean quicker interventions, a reduction in unnecessary ER visits and better ongoing care for chronic issues like asthma or hypertension. TytoCare’s extensive health dataset of over 7 million recorded exams boosts both diagnostic confidence and the accuracy of models.
This move also aligns with a broader trend in healthcare — bringing diagnostics closer to the patient. With more people wanting care at home, integrated AI diagnostics might soon be the norm instead of just a unique feature.
However, the execution of this plan will be key. The rollout is set to begin with a select group of customers, which indicates TDOC is cautiously testing adoption, utilization rates and reimbursement alignment. If executed well and reflects TytoCare’s historical performance, then this integration could become a scalable advantage.
TDOC’s Price Performance
Year to date, TDOC shares have declined 23% against the industry’s growth of 4.9%.
Image Source: Zacks Investment Research
TDOC’s Zacks Rank & Key Picks
TDOC currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the Medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , Universal Health Services, Inc. (UHS - Free Report) and Veracyte, Inc. (VCYT - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.12 per share has witnessed three upward revisions in the past 30 days against no movement in the opposite direction. BrightSpring Health Services beat earnings estimates in each of the trailing four quarters, with the average surprise being 45.1%. The consensus estimate for current-year revenues is pegged at $12.7 billion, suggesting 12.8% year-over-year growth.
The Zacks Consensus Estimate for Universal Health’s current-year earnings of $21.67 per share has witnessed six upward revisions in the past 30 days against no movement in the opposite direction. Universal Health beat earnings estimates in each of the trailing four quarters, with the average surprise being 15.2%. The consensus estimate for current-year revenues is pegged at $17.4 billion, suggesting 9.7% year-over-year growth.
The Zacks Consensus Estimate for Veracyte’s current-year earnings of $1.42 per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction. Veracyte beat earnings estimates in each of the trailing four quarters, with an average surprise being 45.1%. The consensus estimate for current-year revenues is pegged at $508.6 million, suggesting 14.1% year-over-year growth.